Indivior stuck to its 2018 revenue guidance on Friday but said it would revisit the forecast if Dr Reddy's launches the cheaper drug. Shares in British drugmaker Indivior rose on Monday after a US Court granted a temporary restraining order blocking Dr Reddy's Laboratories from launching a generic version of Indivior's best-selling opioid addiction treatment. Indivior shares rose more than 6 per cent in early trade, after falling by nearly a third on Friday after Dr Reddy's and US-based Mylan NV received FDA approval for a generic version of Suboxone Film, which generates 80 per cent of Indivior's revenue.
To Get Free Trial
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
To Get Free Trial
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
No comments:
Post a Comment